The profit to be gained by testing Danish blood donors for hepatitis B surface antigen (HBsAg) with a third generation technique instead of the currently used immunoelectrophoresis was investigated by additional screening of 48 750 blood units by radioimmunoassay three weeks after donation. Twenty nine units were positive for HBsAgon radioimmunoassay(O-059%).Onlysix of these were found by immunoelectrophoresis (0 012%). Most of the 23 donors positive on radioimmunoassay and negative on immunoelectrophoresis were healthy carriers of HBsAg (20) 
Introduction
During the past decade routine screening of Danish blood donors for hepatitis B surface antigen (HBsAg) has been by immunoelectrophoresis. The use of this rather insensitive test for detecting HBsAg has been justified by the fact that the incidence of hepatitis B is low in Denmark compared with many other countries. Only 10-20 cases of hepatitis B associated with transfusion are registered each year. In countries with a high prevalence of HBsAg the use of third generation techniques (radioimmunoassay and enzyme methods) can show the presence for HBsAg using third generation techniques in areas of high prevalence substantially reduces hepatitis B associated with transfusion.2 These highly sensitive tests are now recommended for routine screening of donors in the United States and most countries in western Europe. The profit to be gained from introducing third generation techniques in areas of low prevalence like the Scandinavian countries, however, is unknown. Most of the donors who yield positive results on testing for HBsAg in these countries are healthy carriers of HBsAg,4 and the potential risk of infection from using their blood in transfusions is still not clear. In this study we determined the prevalence of blood donors positive for HBsAg who were detectable only by radioimmunoassay and investigated whether blood from these donors caused infection.
Methods
We received serum samples from all units of blood gathered in the Copenhagen area from 4 January to 7 June 1982 for additional testing for HBsAg by third generation technique (Ausria II-125, Abbott). We registered the age and sex of each donor and whether he or she had been tested for HBsAg by immunoelectrophoresis or a third generation technique previously. The radioimmunoassay was performed 21 days after the serum sample had been received, at which time the blood unit would have been either used or discarded. Serum samples that were repeatedly positive for HBsAg were tested for hepatitis B e antigen (HBeAg), antibody to HBeAg (anti-HBe), and antibody to hepatitis B core antigen (anti-HBc) ( Fifteen of the 23 blood units that were positive on radioimmunoassay and negative on immunoelectrophoresis were transfused: of eight units obtained from the group of donors who were healthy carriers of HBsAg, five were outdated and three were discarded. The disclosure of the presence of HBsAg and consequent discarding of the blood in these three cases was due to supplementary testing by a third generation technique in two cases (because the donor was implicated in a case of hepatitis B associated with transfusion and because the plasma unit was intended for production of factor VIII, respectively) and in one case was because the donor underwent plasmapheresis twice in three weeks (to obtain antibodies against varicella virus) and at the second plasmapheresis HBsAg was found on screening by immunoelectrophoresis.
Thus fifteen patients received blood that was positive on radioimmunoassay and negative on immunoelectrophoresis. Twelve of these blood units came from healthy carriers of HBsAg. Among the 12 recipients of these units, four developed acute hepatitis B, which became fulminant and fatal in one case; the remaining three patients developed symptoms and required admission to hospital but otherwise had an uncomplicated course. A further patient became a healthy carrier of HBsAg, one was immunised against hepatitis B virus-that is, seroconversion took place without biochemical abnormalities or symptoms of liver disease-and one had presumably been positive for anti-HBs at the time of transfusion as anti-HBs was already present in a high titre at the first follow up examination. Four patients died from their primary disease without developing hepatitis (after four days, four days, four weeks, and 16 weeks). The patient who died 16 weeks after transfusion was positive for HBsAg for several weeks before death but showed no clinical or biochemical signs of acute hepatitis. Postmortem liver biopsy specimens showed no histological abnormality. In a 6 week old girl nothing happened either serologically or biochemically.
Of the three patients who received blood from the donors with acute hepatitis B, chronic persistent hepatitis B, and cirrhosis positive for HBsAg, respectively, the first died five days after transfusion, the second was positive for anti-HBs before the transfusion, and the third was immunised against hepatitis B virus.
Discussion
In this study HBsAg was detected in 0 059% of the blood donors by radioimmunoassay compared with 0-012% by immunoelectrophoresis-that is, there was a fivefold increase in the detection of blood donors positive for HBsAg when radioimmunoassay was used instead of immunoelectrophoresis. This difference, however, applies only to a population of donors who have not been tested by radioimmunoassay before. In time the rate of detection of HBsAg by radioimmunoassay will decrease owing to the lower prevalence in repeat donors compared with first time donors. In the group of first time donors the prevalence of HBsAg was 0-13% by radioimmunoassay and 0-065% by immunoelectrophoresis. Thus the estimated profit in using radioimmunoassay instead of immunoelectrophoresis is a twofold increase in the detection of HBsAg. This is in accordance with the findings of Dodd, The chief purpose of screening for HBsAg is not to identify blood donors positive for HBsAg but to reduce hepatitis B associated with transfusion. Thus the profit to be gained from screening depends not only on the number of donors positive for HBsAg who are identified but also on the infectivity of blood from these donors. As most donors in Denmark who are positive for HBsAg are healthy carriers of HBsAg the profit depends mostly on the infectivity in the healthy carrier state. The predominant opinion has been that the presence of HBeAg indicates active viral replication, so that material positive for HBeAg is highly infectious whereas material negative for HBeAg and positive for anti-HBe is non-infectious or carries an extremely low risk of infection. The expected outcome of receiving blood from a healthy carrier of HBsAg should therefore be immunisation against hepatitis B virus. This study showed, however, that four out of seven recipients susceptible to infection with hepatitis B virus developed acute hepatitis B after receiving blood from a healthy carrier of HBsAg. Thus we conclude that healthy carriers of HBsAg are highly infectious as blood donors, probably because of the large amount of material transmitted. The system based on the presence of HBeAg and anti-HBe seems to be of no value in predicting the outcome in recipients of blood positive for HBsAg.
